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ABSTRACT The interleukin 2 (IL-2) gene is subject to
two types of regulation: its expression is T-lymphocyte-
specific and it is acutely dependent on specific activation
signals. The IL-2 transcriptional apparatus integrates multi-
ple types of biochemical information in determining whether
or not the gene will be expressed, using multiple diverse
transcription factors that are each optimally activated or
inhibited by different signaling pathways. When activation of
one or two of these factors is blocked, IL-2 expression is
completely inhibited. The inability of the other, unaffected
factors to work is explained by the striking finding that none
of the factors interacts stably with its target site in the IL-2
enhancer unless all the factors are present. Coordinate occu-
pancy of all the sites in the minimal enhancer is apparently
maintained by continuous assembly and disassembly cycles
that respond to the instantaneous levels of each factor in the
nuclear compartment. In addition, the minimal enhancer
undergoes specific increases in DNase I accessibility, consis-
tent with dramatic changes in chromatin structure upon
activation. Still to be resolved is what interaction(s) conveys
T-lineage specificity. In the absence of activating signals, the
minimal IL-2 enhancer region in mature T cells is apparently
unoccupied, exactly as in non-T lineage cells. However, in a
conserved but poorly studied upstream region, we have now
mapped several novel sites of DNase I hypersensitivity in vivo
that constitutively distinguish IL-2 producer type T cells from
cell types that cannot express IL-2. Thus a distinct domain of
the IL-2 regulatory sequence may contain sites for compe-
tence- or lineage-marking protein contacts.
Dual Regulation of the Interleukin 2 (IL-2) Gene:
Activation Dependence and Cell-Type Specificity
T cells control the magnitude of the immune response by their
highly regulated secretion of cytokines. IL-2, which drives the
proliferation of T cells, B cells, and natural killer cells, is one
of the best characterized of these cytokines. The expression of
IL-2 is controlled almost entirely at the transcriptional level,
and the control is stringent: non-T cells have rarely if ever been
reported to express this gene, and even T cells do not transcribe
the IL-2 gene except in immediate response to an appropriate
activating signal. When the IL-2 gene is induced, its expression
is transient; the kinetics and magnitude of this response are
highly influenced by modulating signals from the environment.
Thus the mechanism controlling transcription of the IL-2 gene
uses at least two different kinds of information: one, whether
or not the cell is a T cell; and the other, exactly what kinds of
signaling pathways are currently activated in that cell.
To explain the mechanism through which IL-2 transcription is
regulated, we need to define how these two kinds of informa-
tion-one stable and heritable through cell lineage, and the other
transient and subject to constant physiological revision-are
conveyed to the gene. Several possibilities can be envisioned. (i)
One is that IL-2 expression depends on at least one transcription
factor that is only present in T-lineage cells. Such a factor might
be a constitutive T-cell lineage identifier. If this is the case, then
the way a specific factor conveys lineage information to the IL-2
gene depends on the way in which it interacts with factors that
respond to transient activation pathways. (ii) A second possibility
is that there is a factor that is only present or activated in response
to a T-cell-specific activation pathway. In this case, the IL-2 gene
might in principle be regulated by a single factor, but that factor's
own availability would be the resultant of both lineage-specific
and activation-specific mechanisms. (iii) A third possibility is that
cell-type specificity and activation dependence are mediated by
temporally separate mechanisms: the IL-2 locus may be "opened"
in a lineage-specific way that is necessary, but not sufficient, for
transcription to occur; then activation-dependent factors execute
transcriptional initiation in response to immediate physiological
conditions. In this last possibility, the activation-dependent fac-
tors that control transcriptional initiation need not be T-cell
specific at all, so long as the repression of the locus in non-T cells
is sufficiently tight. There are also versions of each of these
mechanisms in which the critical element is the absence of a
negative regulator, instead of the presence of a positive regulator.
It is relevant, in thinking about these mechanisms, that the
"lineage-specification" and the actual expression of IL-2 ap-
pear to be widely separated in developmental time. Normal
resting T cells express no baseline IL-2 transcripts at levels
detectable by in situ hybridization. The overwhelming majority
of T-cell precursors, differentiating in the thymus, also express
no detectable IL-2 mRNA (1-4). However, the capacity to
express IL-2 in response to an artificial inducing signal appears
very early in T-cell development. T cells differentiate from
hematopoietic stem cells throughout life, in a programmed
series of events including ordered rearrangement of the genes
that encode the T-cell receptor for antigen and selection of
cells with appropriate recognition specificities (5, 6). Devel-
oping T cells are already competent to express IL-2 in response
to induction before undergoing any T-cell receptor gene
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rearrangement events (7) (R. A. Diamond, S.B.W., K. Owada-
Makabe, and E.V.R., unpublished observations), and it even
appears that excellent potential IL-2 producers are among the
most primitive cell types in the thymus (7-9), in a population
that includes cells that are not yet fully committed to a
T-lineage fate (10, 11). This responsiveness contrasts with the
inability of non-T bone marrow hematopoietic cells to make
IL-2 generally, and the complete lack of IL-2 expression by any
somatic non-hematopoietic tissue whatsoever. Thus, some
alteration at a molecular level confers inducibility on the IL-2
locus at a particular, early point in the specification of T-
lineage cells. This inducibility is then a heritable characteristic
of cells in the T lineage, separated from IL-2 expressionperse,
which can remain latent indefinitely or be used at any time in
response to stimulation.
While this developmental picture may favor a model of IL-2
regulation with separate mechanisms controlling activation and
cell-type specificity, there is evidence that sets of information
complex enough to include cell-type specificity can be integrated
in the response of the gene to activating signals alone. IL-2
expression, although readily inducible in most mature T cells, is
also readily inhibited by any of a variety of developmental or
physiological conditions (Fig. 1). Some of these, like exposure to
glucocorticoid hormones or elevation of intracellular cAMP,
are common occurrences in T cells in vivo, and thus are likely
to play significant roles in determining when and where IL-2
is actually made. The expression of IL-2 mRNA can also be
significantly enhanced under some physiological circum-
stances, for example by costimulation of the T cell through the
CD28 cell-surface receptor along with the T-cell receptor for
antigen, and in immature T cells by costimulation with the
macrophage-derived cytokine IL-1 (1). Whereas it remains
controversial how much of the effect ofCD28 is transcriptional
and how much posttranscriptional (12-14), it is clear that IL-1
can enhance transcription from the IL-2 promoter (15). Al-
though not all the biochemical mediators in the modulatory
pathways are yet defined, enough is known to indicate that at
least three separate pathways are involved (discussed further
below). Thus activation stimuli are modulated by combinato-
rial interactions among different signaling pathways in deter-
mining the rate and duration of IL-2 transcription.
Regulatory Sequences and Transcription Factors for IL-2
Induction
All the effects of the inducing agents and interfering agents
described above appear to be mediated through an '300-bp
minimal enhancer region immediately upstream of the transcrip-
tional start site (rev. in ref. 16). This conclusion has emerged from
an extensive set of transient transfection experiments introducing
IL-2 promoter constructs into tissue culture T-cell lines and
assaying their responses to activating stimuli. This region is highly
conserved between mouse and human (86% identical) (17, 18),
and essentially the whole extent of this minimal enhancer is
packed with binding sites for multiple transcription factors, as
shown by in vitro footprinting (18-20) and electrophoretic mo-
bility shift experiments with nuclear extracts (reviewed in refs. 21
and 22). Many of these sites are bound by transcription factors
that are related or identical to well-known factors that mediate
activation responses in other cell types-e.g., AP-1 and NF-KB.
Others are bound by ubiquitous factors that are also constitutive,
such as Oct-1. There are also factors that were novel when first
reported, some of which have subsequently been better charac-
terized: an important example is NF-AT. Other factors have
remained controversial ["CD28RC" (14,20,23,24)], while others
play roles which remain to be fully elucidated ["Spl-like" (25, 26)
and "TGGGC factor" (27, 28)]. In spite ofthe multiplicity of these
factors, their sites are not functionally redundant. Point mutations
or small deletions at almost any one of the known binding sites
throughout the minimal enhancer can cause severe effects on
transcription. Thus induction of the IL-2 promoter in response to
activating agents depends on the binding of multiple distinct
factors at multiple sites.
Different Signaling Pathways Differentially Mobilize
Induction-Dependent IL-2 Transcription Factors
A notable feature of the factors used to drive IL-2 induction
is that they each respond to somewhat different conditions of
signaling. Some are constitutive: for example, Oct-1 (29, 30)
and a Spl-like factor (25, 26) that binds at least twice at the
borders of the minimal enhancer (27). The others require
"activation" to exhibit their binding activities in nuclear ex-
tracts, but the activation pathways involved are different.
Three important factors have been studied in some detail.
(i) NF-AT. NF-AT plays a role that we can paraphrase as the
key transducer of the information that the T-cell receptor for
antigen, the generator of Ca2+ signals, has been engaged. NF-AT
is expressed constitutively but can only enter the nucleus after
release, via the Ca2+-dependent phosphatase calcineurin, from a
cytoplasmic tethering site (rev. in ref. 21). NF-AT is actually a
family of factors with divergent Rel domains, each of which is
expressed in a somewhat different cell-type distribution (31-35),
but all of which appear to have their activities regulated in the
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same ways. Any condition that interferes with Ca21 flux and/or
with calcineurin activity specifically prevents NF-AT from par-
ticipating in IL-2 expression. CSA or FKS06, which inhibit
calcineurin, strongly inhibit NF-AT availability but with much less
severe effects on other factors (36). However, NF-AT DNA
binding activity is apparently unaffected bycAMP, glucocorticoid
hormones, or by the changes in signaling that occur in anergized
(paralyzed) T cells (28, 37-39).
(ii) NF-acB. The role of NF-KB can be paraphrased as a
messenger of stress: a situation where an immune response is
needed to stave off danger. NF-KB consists of any of a variety
of canonical Rel-domain family dimers, with p50 (NFKB1)
homodimers, pSO-p65 (relA) heterodimers, and pSO-c-Rel
heterodimers most often found in T cells. Of these, only
pSO-p65 and pSO-c-Rel play an activating role in IL-2 gene
regulation. NF-KB activity can be induced through a variety of
pathways, including two Ca2+-independent ways (40, 41): (a)
by phorbol esters presumably activating Ras via protein kinase
C, or (b) by a "stress-induced" sphingomyelinase-dependent
pathway. Part of the activation of NF-KB is due to the
posttranslational release of pre-formed factor from a cyto-
plasmic tethering component, IKB, while part may be due to de
novo synthesis (reviewed in ref. 40). A strong inhibition of the
activating forms, p65-pSO or c-Rel-pSO, results when intracel-
lular cAMP is elevated (28, 37, 42), although the mechanism
for this inhibition is not yet understood. Under some condi-
tions, also, calcineurin inhibitors like CSA can inhibit optimal
quantitative release of NF-KB from inhibition (43, 44). The
ability of these inhibitors to block NF-KB availability depends
on the path used to stimulate NF-KB; however, since the
blockade can be overridden by adding the inflammatory
cytokine tumor necrosis factor-a (28), which activates NF-KB
through the separate sphingomyelinase-dependent cascade.
(iii) AP-1. AP-1, another complex factor family, has a more
subtle role, which incorporates both information about the acti-
vation conditions facing the cell and information about the
developmental status of the cell itself. In T cells, a combination
of Ca2+ and protein kinase C signals induces AP-1 DNA-binding
activity better than protein kinase C alone (15, 45), and either
cAMP elevation or IL-1 costimulation (in susceptible cells) leads
to a further enhancement in AP-1 binding activity (15, 28, 37).
Under various physiological conditions of cellular nonresponsive-
ness, AP-1 DNA-binding activity is not available to the cell at all
[anergy (39, 46) and cortical thymocytes (25, 47)]. However, the
ability of AP-1 to activate transcription is regulated not only by
its capacity to bind DNA, but also by its subunit composition
(dimers composed of any of three different Jun family members
and/or any of four or five different Fos family members).
Different stimulation conditions activate the synthesis of different
Jun and Fos family members (45, 48, 49), and although the
binding affinities of most Fos/Jun complexes are very similar,
their effects on transcription are distinct.
The DNA-binding activities of these diverse factors are nec-
essary but not sufficient for their transcriptional activity [e.g.,
NF-AT (37, 50) and NF-adB (51)]. This is particularly true for
AP-1, since the ability of c-Jun and JunD to activate transcription
once bound toDNA depend on their N-terminal phosphorylation
status. The key activating kinase, Jun N-terminal kinase, itself
responds to combinations of signaling pathways (52, 53) in ways
that mimic much ofthe regulation of IL-2 expression. This is likely
to explain the fact that transcription from a concatemer of
optimal AP-1 binding sites displays activation requirements sim-
ilar to those of transcription from the whole IL-2 promoter, even
though strong AP-1 binding activity is induced in a much broader
set of conditions (45). Thus AP-1 binding activity is limiting in
some physiological circumstances, while only its trans-activating
activity is limiting in others. FinaLly, and critically, AP-1 appears
to bind to the IL-2 enhancer in close association with other factors
in at least three and possibly as many as five cases: with Oct-1 at
one site (30, 48, 54), with NF-AT at two other sites (reviewed in
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ref. 55), and possibly with additional NF-AT complexes at two
additional sites (20). In each of these cases, the interaction
between AP-1 and the other factor enhances DNA-binding
affinity for both. It is not yet clear how much Fos/Jun family
member selectivity is required for these protein-protein interac-
tions as seen on the full promoter, as distinct from their ability to
bind to isolated AP-1 site oligonucleotides.
The novel factors involved in IL-2 regulation may have still
other sets of activation requirements. An example is the novel
"TGGGC" factor, which binds to a site that could represent a
nonconsensus form of a Su(H) site or a PEBP2a site. The
DNA-binding activity of this factor is induction-dependent and
only partially CSA sensitive like NF-KB, and it is fully inducible
in cortical thymocytes, which can mobilize NF-KB but not AP-1
(27, 56) (D. Chen and E.V.R., unpublished results). Also, like
NF-KB, it is inhibited by elevation of cAMP. However, it is
inhibited with more rapid kinetics than NF-KB in this case, and
unlike NF-KB, its synthesis is not restored by costimulation
with tumor necrosis factor a (28). Thus this additional factor
exhibits a distinct pattern of regulation by signaling pathways.
Coordinated Binding as a Basis of the Requirement for
Multiple Transcriptional Activators
Fig. 2 presents a summary of the availabilities of different
transcription factor binding activities observed in nuclear extracts
from cells under different conditions of stimulation. As shown in
Fig. 2, in each of the cases where IL-2 induction is blocked, at least
one of the transcription factors with sites in the minimal enhancer
is missing. In each of these cases, however, there are many factors
that are present and unaffected. As with the question ofwhy any
of a number of different single-site mutations should block
expression of the IL-2 gene, this observation raises the question
of how IL-2 gene expression can be so dependent on the presence
of all of these factors.
One possibility is that the factors that are present are not
really active. This might be the case if modifications of all the
factors are needed to endow them with transcriptional activa-
tion capability, as in the case of AP-1. This would then require
that these modifications are all executed correctly only under
conditions that coincide with the presence of all the transcrip-
tion factors. In this case, all "signal integration" would really
be carried out by the modifying enzyme(s). Another possibility
is that factors of diverse types really must be bound to the
enhancer to make it work correctly, because their distinct
activation domains deliver qualitatively different, complemen-
tary interactions with the TATA-binding protein-associated
factor (TAF) components of the basal transcriptional appara-
tus (as suggested in refs. 58 and 59). However, if such a
requirement were enforced stringently, it would be hard to
explain the repeated observation that multimers of a single
factor binding site from the IL-2 enhancer can also work well
to drive reporter expression in an IL-2-like way. A third
possibility is that the factors need to be present together to
stabilize each other's interactions with the DNA. In this case,
assembly of the transcription complex itself would be a mech-
anism for integrating contributions from factors at the termini
of different signaling pathways, and the requirement for
multiple factors would be based on an inability of the key
factors to bind stably on their own.
Whereas the first and second possibilities can only be tested
by an extensive biochemical analysis of individual transcription
factors and their interactions with the basal apparatus, the
third possibility can be tested directly by analysis of the actual
protein-DNA contacts formed on the IL-2 enhancer in acti-
vated T cells. We have done this in a series of studies using in
vivo footprinting of the IL-2 locus in living T-lineage cells
treated with the DNA-alkylating agent, dimethyl sulfate
(DMS), which reacts with G residues in the major groove (27,
28). In these studies we compared nonactivated T-lineage cells,
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T cells activated under optimal conditions for IL-2 expression,
and T cells activated under conditions in which the binding
capacities of different subsets of transcription factors in vitro
are known to be inhibited. The question we asked was whether
the occupancies of individual transcription factor binding sites
in the endogenous IL-2 regulatory region depended only on
the amount of binding activity of the relevant factor, as assayed
in nuclear extracts, or alternatively, whether binding itself in
vivo might depend on activities other than those that we could
measure with these isolated sites.
The results of these studies show that IL-2 transcription
factors are acutely interdependent for their binding to the
DNA in vivo. Regardless of the activation requirements of the
individual factors, the sites they bind in the IL-2 minimal
enhancer are either all occupied in vivo-if and only if all
factors are present; or all empty-in every other case (27, 28).
Furthermore, whether the inhibitor used is CSA, which pref-
erentially inhibits the induction of NF-AT DNA-binding ac-
tivity, or forskolin, which preferentially inhibits the mobiliza-
tion of NF-KB and TGGGC factor DNA-binding activities, the
result is the same: the footprints at all sites, including the AP-1
sites and the sites of constitutive factor binding, are abolished.
This shows that neither NF-AT nor any of the other factors can
bind to the IL-2 minimal enhancer DNA autonomously in vivo,
however well they bind to their isolated target sites in vitro.
There are two possible explanations for these results. First, as
we have proposed elsewhere (28), a straightforward interpretation
is that there is no single "master regulator" for the IL-2 gene;
instead, multiple types of factors, each responsive to different
signaling pathways, must simultaneously bind to the DNA and
interact to stabilize each other's binding. This interpretation
envisions that stable transcription factor binding at the IL-2
minimal enhancer occurs only in the context of a multifactor
complex with direct or indirectly mediated protein-protein inter-
actions linking each factor with multiple partners (60, 61)). This
would provide an architectural mechanism for "checking off' the
occupancies of sites over most of the regulatory region DNA.
Second, the experiments we have done leave open the
possibility that there is a kind of "master regulator," if this
master regulator is AP-1. As discussed above, AP-1 is differ-
entially modified or composed of different subunits under the
different stimulation conditions we have tested, either via
effects on Jun N-terminal kinase or via preferential induction
of JunB versus c-Jun. The key is that these modifications, at
least in response to CSA and forskolin, do not decrease the
efficiency with which AP-1 binds to its isolated target DNA
sequence. However, for the protein-protein interactions lead-
ing to enhancement of Oct-1/AP-1 and NF-AT/AP-1 DNA-
binding affinities (31, 54), there is some evidence that the exact
composition of the AP-1 can strongly influence the outcome
(48). Thus, the form of AP-1 available after stimulation in the
presence of CSA or forskolin might fail both to stabilize Oct-1
(at one site at least) and to stabilize NF-AT (at two to five sites).
Note that even if AP-1 is a master regulator in this sense, it still
cannot bind its DNA target sites autonomously in vivo: it
controls expression through its interactions with other factors.
Thus, in both of these scenarios, the integration of signals to
control IL-2 expression depends on factor-factor interactions
as well as on factor-DNA interactions.
Complex Assembly and Disassembly Cycles for Dynamic
Signal Integration
A striking feature of the in vivo footprinting pattern is the
apparent lack of evidence for protein-DNA contacts over the
minimal enhancer in unstimulated, resting T cells. Footprints
only appear at any site when they appear at every site-namely
under optimal conditions of induction. If the appearance of
these stable DNA-protein contacts is the outcome of a mul-
tifactor assembly process, then in principle the nucleation of
initial subassemblies might be separable from the addition of
later, stabilizing components. However, it has not yet been
possible to detect any partial complexes that might be kinetic
intermediates. Similarly, even once formed, the multifactor com-
plexes remain unstable. When an inhibitor such as CSA or
forskolin (to elevate cAMP) is added to cells that are already
responding to stimulation, we find that the footprints over the
whole IL-2 minimal enhancer disappear rapidly, with a time-
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course that closely follows the timecourse of disappearance of the
free target factor from the nucleus (NF-AT or NF-KB, respec-
tively) as measured by binding activity (28). Thus, not only do
individual protein-DNA contacts appear to be too weak to form
autonomously, they also appear to be readily reversible even after
a full transcription complex has assembled (28).
This mechanism contrasts with the stable occupancy ob-
served at sites of constitutive transcription factor binding-
e.g., in the IL-2 receptor a-chain and metallothionein-I genes
(62, 63). However, by contrast with other well-studied genes,
it is important to realize that the IL-2 gene is normally
designed to remain silent, even in cells of the right lineage to
express it, and to return to silence quickly after its expression
has been induced. Structural characteristics of the binding sites
themselves support this interpretation. Of all the sites for
known factors in the IL-2 minimal enhancer, none match the
consensus for optimal binding (64). Instead, base changes that
critically weaken the DNA binding affinities of these known
factors are conserved perfectly between the murine and hu-
man versions of the enhancer (17). When any of these sites is
mutated to match the consensus, it damages the induction-
dependence and/or cell-type specificity of the IL-2 promoter
(64). Taken alone, this finding could mean that there are
T-cell-specific members of the AP-1, NF-KB, and Oct families
that bind most tightly to the IL-2 versions of these sites,
whereas the "consensus" versions are preferred by the ubiq-
uitous (and canonical) members of these families. However,
our data on the weakness in vivo of these contacts in activated
T cells argue that it is not the need for novel high-affinity
interactions, but rather for low-affinity interactionsperse, that
is important for correct IL-2 regulation. We can think of the
systematically weakened protein-DNA contacts throughout
the minimal enhancer, and the resulting requirement for
simultaneous factor binding, as one mechanism for maintain-
ing the lack of background IL-2 expression.
The apparently "empty" status of the enhancer in resting T
cells appears inconsistent with several lines of evidence sug-
gesting that particular transcription factors act as negative
regulators of IL-2 transcription. Candidate negative regulators
include the p5O2 form of NF-KB, which presumably antago-
nizes p65-pSO and c-Rel-p5O forms at the NF-KB site (51);
Nil-2A, a zinc finger protein that binds to a distinct site at about
-110 (65); Ets-1, which like other Ets family proteins may bind
at or near the NF-AT site(s) (66, 67); and a less characterized
but intriguing 45-kDa factor that also binds to the NF-AT site
(68). We have seen no evidence for DMS footprints in vivo at
any of these sites, either in resting EL4 cells or in certain cell
types that maintain high levels of p502 complexes constitutively
(27). Thus our data make it seem unlikely that these factors
work by stable occupation of their sites and competitive
exclusion of positive factors. This conclusion is provisional, of
course, because the readily stimulated EL4 cells that we have
had to study may lack some of the regulatory apparatus of
normal T cells. However, the requirement for continual reas-
sembly of positive transcription complexes may indicate the
way these negative factors could work: to interact with their
sites just long enough to provide kinetic, rather than equilib-
rium, interference with the interactions needed to stabilize the
multifactor complexes in the minimal enhancer.
In any case, the absence of any long-term "locking-in" of the
activating transcription factors, once they do bind to the minimal
enhancer, means that the probability of a transcription complex
being present on the gene is closely linked kinetically to the
instantaneous concentration(s) of whichever factor(s) are most
limiting. This is a mechanism that makes the IL-2 transcriptional
initiation rate continuously sensitive to immediate changes in the
signaling physiology of the T cell. The structure of the enhancer
thus provides a way that the amount of IL-2 produced can be
precisely modulated in the course of an ongoing immune re-
sponse. At another level, the use of this mechanism emphasizes
the continuous accessibility of the IL-2 locus to equilibrate with
nuclear pools of transcriptional activators in T cells. As discussed
further below, this establishes constraints on the mechanisms
making IL-2 expression T-cell specific.
The Problem of T-Cell Lineage Specificity
With this picture of the mechanism that governs IL-2 transcrip-
tion in response to stimulation, we can return to consider how
IL-2 expression is rendered T-cell specific. Three general kinds of
models were described at the beginning of this manuscript, and
these are summarized diagrammatically in Fig. 3. In the first
model, the IL-2 locus is "open" everywhere, but can only be
transcriptionally activated if at least one T-lineage-specific factor
is present. In the second model, again the locus is open in all cells,
but the ability of factors-which may not themselves be absolutely
T-cell specific-to activate transcription depends on a T-cell-
specific signaling pathway. In the third model, the T-cell speci-
ficity resides not solely in the factors used to drive IL-2 expression
or in their posttranslational modifications, but rather resides in
the state of accessibility of the IL-2 locus in chromatin, which is
opened only as cells enter the T-cell lineage.
For now, the second model (T-lineage-specific activation of
factors) is difficult to test except by excluding the alternatives.
However, we can consider evidence relevant to the first and
third models. To distinguish among them, we can ask: Are
there unique T-cell-specific trans-acting factors that play the
rate-limiting role in IL-2 gene expression, and is there any
stable T-lineage-specific cis-alteration in the state of the IL-2
chromatin prior to induction?
Many of the factors that participate in IL-2 induction are clearly
ubiquitous, including AP-1, NF-KB, and Oct-1, and therefore are
eminently excluded as sources of T-lineage specificity. The initial
discovery of NF-AT was thought to provide a T-cell-specific
factor, as NF-AT activity was found only in activated T cells (69).
Subsequent characterization, cloning, and analysis of the expres-
sion of the NF-AT genes have shown that the binding activity is
contributed by a multi-gene family, and that members of this
family are expressed in many tissues other thanT cells (31-34, 70).
Thus the expression ofNF-AT (even with access to AP-1, NF-KB,
and Oct-1) is not sufficient to make a cell into an IL-2 producer.
To date, none of the factors needed to drive IL-2 expression from
the minimal enhancer are clearly shown to be T-cell specific.
The suggestion that lineage specificity may be regulated at the
level of chromatin opening might also appear unlikely. In vivo
DMS footprinting has not shown any pattern of occupancy of G
residues in the minimal enhancer that distinguishes T cells, prior
to stimulation, from cells of any other lineage (27). The minimal
enhancer region not only appears "empty" in unstimulated T
cells; it is equally empty in non-IL-2 producing hematopoietic
cells, such as 32D clone 5, and non-IL-2 producing cells of other
types altogether, such as U cells and lOT1/2 cells. There is no
evidence for constitutive repression in non-IL-2 producing cell
types, at least not through a mechanism of stable contacts with
enhancer region G residues in the major groove. The difference
is that in the T cells activation results in occupancy of these
sequences, whereas in the non-T cells the IL-2 enhancer remains
unoccupied even after stimulation (27) (S.B.W., unpublished
results). Taken alone, these observations could point to a mech-
anism of lineage specificity that is exercised entirely through
T-cell-specific signaling pathways.
The point is important enough to deserve a better test,
however. Exclusive use of DMS would not allow us to detect
minor groove binding factors, such as the T-cell-specific high
mobility group box factors Sox-4 and TCF-1, and high mobility
group box proteins can have either positive or negative effects on
expression (61, 71). The inability to detect contacts on anything
but G residues is particularly unsatisfying for a sequence that is
as highly A/T-rich as the IL-2 5'-flanking region. In fact, using an
altered protocol that visualizes effects at A as well as G residues,
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FIG. 3. Three models for combining stable T-cell lineage specificity with rapid, transient activation dependence of IL-2 expression. As a "worst
case" scenario, the non-T cells are represented as activated, so that any ubiquitous activation-dependent factors (rectangles) are present in those
cells as well as in activated T cells. The T-cell-specific components differ as described in the text. In model 1, a trans-acting factor (triangle) is uniquely
present in T cells, which is required to interact with the activation-dependent factors to activate transcription (black right-angled arrow). In model
2, the activation-dependent factors are of the wrong composition or possess the wrong posttranslational modification for use at the IL-2 promoter
(black rectangles) unless activated by T-cell-specific signaling pathways (open arrows). In model 3, the IL-2 gene is not accessible in non-T cells,
but only in T cells, due to a stable cis-modification of chromatin (border-forming factors represented by ovals) which precedes activation.
Brunvand et al. (72) have reported that some contacts may occur
near the TATA boxes of the human IL2 gene even prior to
stimulation. Furthermore, although the -300-bp minimal en-
hancer is sufficient to control expression in transient expression
experiments, it is not the only region likely to be important for
IL-2 regulation in vivo. An early survey of the IL-2 gene by
Siebenlist et al. (73) reported regions of DNase I hypersensitivity
outside of the minimal enhancer in resting T cells. There is
evidence for evolutionary conservation of sequences beyond the
minimal enhancer as well. Noncoding sequences from approxi-
mately -600 to beyond +45 with respect to the transcriptional
start site are all conserved to >80% identity between mouse and
human, significantly better conservation than within the coding
regions themselves (17). Finally, it is noteworthy that in numerous
attempts to generate transgenic mice in which a reporter gene is
driven from the IL-2 promoter, none have succeeded using less
than the -'600-bp version of the 5'-flanking region (74-76). In
recent work, therefore, we have compared IL-2 regulatory se-
quence footprints in T and non-T cells over - 1 kb from -600 to
+350, and we have supplemented the DMS analysis with two
additional in vivo footprinting reagents, DNase I and KMnO4.
This broadened search has provided new evidence for consti-
tutive differences at the IL-2 locus between the protein-DNA
interactions in resting T cells and those in non-T cells. The new
reagents confirm the analysis with DMS, insofar as the minimal
enhancer region (-300 to -45) still appears virtually unoccupied
in T cells prior to stimulation. One exception is that we confirm
some of the contacts seen by Brunvand et al. (72) in A/T rich
regions close to the TATA boxes. Upon stimulation, the DNase
reactivity increases sharply over several regions of the minimal
enhancer (unpublished data), in parallel with the appearance of
DMS footprints. However, outside the minimal enhancer region,
a new pattern of occupancy is seen. In the region from -300 to
-600, no contacts on G residues are detected by DMS footprint-
ing in stimulated or unstimulated cells. Even so, a series of specific
residues (between about -350 and -460) are maintained in a
DNase hypersensitive state in the resting T cells, as shown in Fig.
4 (compare lanes 1 and 2). Upon stimulation of the cells, the
degree of DNase hypersensitivity of these sites increases (Fig. 4,
compare lanes 2 and 3), and in fact one stimulation-dependent
alteration of anA residue at -410 can be detected byDMS as well
(data not shown; unpublished data). KMnO4 also detects a
structural distortion of the DNA in this region. Thus the precise
conformation ofDNA and protein-DNA complexes at these sites
may change with activation. However, the most important feature
of these novel DNase hypersensitivities is that they are not seen
in any cells of non-IL-2 producing lineage that we have examined
(Fig. 4, lanes 4 and 5).
The initial identification of these sites provides specific candi-
date sequences to test for interaction with a potential lineage-
marking protein or protein complex at some discrete stage of
T-cell development. Thus far, it is not certain what proteins might
be playing a role. The general lack ofDMS footprints at these sites
indicates that the factors which bind here constitutively are very
unlikely to be the same ones that occupy easily footprinted sites
in the minimal enhancer upon induction. Serfling et aL (22) have
pointed out that induction-dependent Ets-like binding proteins
(GABP) and other factors might occupy sites between -500 and
-420. These sites are not footprinted with DMS, but fall within
the range of DNase hypersensitive sites seen in both stimulated
and unstimulated cells. The -40-bp region centered at -410
contains two palindromes and binding sites for a large number of
factors (unpublished results), and the full identification of these
factors is in pr6gress. Clearly a factor that associated constitu-
tively with the conserved region of this gene in a T-cell-specific
waywould be of great interest as a factor implicated in a T-lineage
identification function.
Architectural Integration of Lineage and Activation
Information in IL-2 Induction
The characterization of potential stable lineage-identifier fac-
tors is at a very early stage, and ideas about their mode(s) of
action must remain speculative for the time being. Of course
L
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FIG. 4. Constitutive DNase I hy-
persensitive sites in the upstream IL-2
enhancer are tissue specific. Hypersen-
sitive sites in the upstream enhancer
are only found in EL4 T cells and not
in two non-T cell lines. Stimulated (+)
or unstimulated (-) cells were treated
with DNase I in vivo. Genomic DNA
was subsequently purified and ana-
lyzed by a modification of the ligation-
mediated PCR method (ref. 77; and
unpublished data), using primers that
amplify the region from -200 to -500.
PCR products were resolved on a 6%
sequencing gel. To determine the in-
herent DNase sensitivity of a region,
purified genomic DNA was treated
with DNase I in vitro (lane N; i.e.,
naked DNA) and then analyzed in
parallel with the in vivo treated sam-
ples. DNase I sensitivities are then
determined by comparing the intensity
of a particular residue to its corre-
sponding site in lane 1 (lane N). Ar-
'NI- +1 + +
4357
..
2 3 4
rows with stars denote residues that are hypersensitive in both
unstimulated and stimulated EL4 cells (lanes 2 and 3) and represent
constitutive hypersensitive sites. Arrows with circles denote residues
that are hypersensitive to DNase I only upon stimulation. Note that
upon stimulation certain constitutively sensitive residues become even
more sensitive to DNase I (residues -357 and -382). In contrast, the
non-T cell lines 32D clone 5 (pre-mast cells, lane 4) and 1OTI/,
(fibroblasts, lane 5), although stimulated, do not display DNase I
hypersensitive sites in this region.
the confirmation of a locus-marking model must await the
identification of discrete factors that are shown to be essential
for opening the IL-2 locus in ontogeny. However, two features
of the DNase and KMnO4 footprinting data suggest how these
stably bound elements might cooperate with the fluid, dynamic
assembly and disassembly of activation mediators at the min-
imal enhancer.
One feature is the spatial separation between the sites of
constitutive DNA perturbation in the upstream region (as
inferred from DNase and KMnO4 footprints distinct from
those of naked DNA) and the whole minimal enhancer. In
addition to the sites in the upstream region, there is also
evidence for a stable KMnO4 footprint in an intronic region
(unpublished data), but no obvious "marking" within the
minimal enhancer itself. These specific assignments are in
agreement with the estimated location of constitutive DNase
hypersensitive sites around the human IL-2 gene, as derived
initially by Siebenlist et al. (73).
The second feature of the footprints is the breadth of the
changes in DNase sensitivity that occur throughout the IL-2
regulatory DNA upon stimulation (unpublished data). The con-
stitutively hypersensitive sites become even more sensitive, and
there are further changes. Not only do specific bases at the
borders of known transcription factor footprints in the minimal
enhancer become hypersensitive, but whole regions of DNA,
10-40 bases at a stretch, are also affected. On the coding strand,
the bases from -110 to -120, -250 to -260, and -300 to -320
become highly sensitive (unpublished data); on the other strand,
a region from -350 to -390 becomes particularly sensitive (for
example, see the bracketed regions in Fig. 5). These broad tracts
of hypersensitive DNA are striking in their strand asymmetry. An
attractive hypothesis is that they represent local distortions of the
DNA between transcription factor binding sites, induced by the
interaction of factors binding upstream of the hypersensitivity
with factors (or with the basal transcriptional apparatus) binding
downstream of the hypersensitivity. The longer tracts may rep-
resent larger distortions or regions of chromatin that become free
of canonical nucleosomes.
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FIG. 5. Stimulation-dependent increases in DNase I sensitivity in vivo
of extended regions of the IL-2 upstream regulatory region. The figure
shows the DNase I footprints over the coding (A) and noncoding (B)
strands of IL-2 DNA from -300 to -400, in stimulated EL4 cells (+ stim)
and unstimulated EL4 cells (- stim) treated with DNase I in vivo, as
compared with EL4 naked DNA treated with DNase I in vitro (lane N).
Samples were processed and analyzed as in Fig. 4. Arrows in the legend
(on the right) indicate the order of samples treated with increasing
amounts of DNase. The figure is a composite of data from different gels,
in which the same samples were electrophoresed for different lengths of
time to obtain a relatively even spacing of bands as a function of length.
All lanes in A were generated by using primers that direct polymerization
toward the distal end of the enhancer, while those in B were generated
by using primers that direct polymerization toward the promoter-
proximal end. To facilitate comparisons of hypersensitivities of corre-
sponding regions of the sequence, the coding and noncoding strand gels
are arranged with their origins at opposite sides of the figure. Brackets
indicate regions of the DNA that increase significantly in DNase sensi-
tivity in stimulated cells. In some cases this increased sensitivity is evident
on both strands-e.g., the region indicated by the brackets near -300. In
other regions, the increase is asymmetrically strand-specific (see brack-
eted region from -350 to -390).
It seems likely, therefore, that cell-type-specific identifiers bind
stably to the distal parts of the conserved IL-2 regulatory region
in T-lineage cells without immediately affecting protein-DNA
contacts over the minimal enhancer itself. Even so, this occu-
pancy can "sensitize" the minimal enhancer, between 50 and 300
bp away, to transcription factor binding at any time that sufficient
components are present to bind cooperatively. There are several
ways that this can happen, based on precedents in the literature.
Sensitization can occur through effects on local and neighboring
nucleosomes, promoting a more open chromatin configuration
(78-82), or through effects on other transcription factors, re-
cruiting them or stabilizing their binding (60, 83, 84). The
distortions of the DNA that we detect in the upstream region can
play a role in either type of mechanism (61, 85). In this case,
because the DNase hypersensitivity in the upstream region (-300
to -600) itself increases on activation, it is possible that the
interactions between the factors binding in the upstream region
and those recruited to the minimal enhancer proper may be
reciprocal. Not only may the upstream factors facilitate transcrip-
tion factor loading at the minimal enhancer, but they may also be
looped around and drawn directly into the complex that activates
IL-2 transcription (see refs. 86 and 87). The identification of
specific, lineage-stable protein-DNA contact sites outside of the
minimal enhancer provides us with a new key to discover exactly
how the architecture of the IL-2 gene transcription complex may
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bring together the mediators of physiological and developmental
information.
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